Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in severe hospitalized COVID-19
NCT04720612Phase 2Unknown
- Sponsor
- McGill University Health Centre
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in coronavirus disease 2019 (COVID-19), sponsored by McGill University Health Centre. Status: unknown.
02
Drugs
omalizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04720612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720612.